Nasus Pharma Ltd. (NSRX)

Nasus Pharma will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$8.00 - $10.00
Shares Offered
1,250,000
Deal Size
$11.25M
Chart not available yet
Data will show when the stock starts trading.
Market Cap81.09M
Revenue (ttm)n/a
Net Income (ttm)-1.53M
Shares Out 9.01M
EPS (ttm)-0.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About SAGE

Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions. Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active powder-based intranasal technology, or PBI, specialized products. To help achieve this we are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1
Country Israel
Stock Exchange NYSEAMERICAN
Ticker Symbol NSRX
Full Company Profile

Financial Performance

Financial numbers in IDR Financial Statements

News

Nasus Pharma IPO Shows Promise But Risks Remain

Nasus Pharma is developing a needle-free intranasal epinephrine spray for severe allergies, showing promising but early trial results in a small population. The company is thinly capitalized, faces a ...

22 days ago - Seeking Alpha

Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO

Nasus Pharma, a Phase 2 biotech developing an intranasal powder for severe allergies and anaphylaxis, filed on Wednesday with the SEC to raise up to $11 million in an initial public offering.

4 weeks ago - Renaissance Capital

Nasus Pharma IPO Registration Document (F-1)

Nasus Pharma has filed to go public with an IPO on the NYSE American.

4 weeks ago - SEC